On January 17, 2024, Eterna Therapeutics Inc. received a notice (the Notice) from the Listing Qualifications Staff (Staff) of The Nasdaq Stock Market LLC (Nasdaq) stating that, due to the appointment of Dorothy Clarke as the company?s general counsel, Ms. Clarke?s subsequent resignation from the committees of the company?s board of directors (the board) and the appointment of Sanjeev Luther as a member of the board, the company no longer complies with Nasdaq?s majority independent board and independent audit committee requirements as set forth in Nasdaq Listing Rule 5605.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.79 USD | +3.12% | -16.75% | -0.28% |
Mar. 15 | North American Morning Briefing : Inflation -2- | DJ |
Mar. 14 | Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-0.28% | 9.68M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ERNA Stock
- News Eterna Therapeutics Inc.
- Eterna Therapeutics Inc. Announces Management Changes